GlassScriptPhysician profile
Frederick Adelana Oni
NPI 1174553226
$2,135.88
in general payments reported to CMS, 2019-2025
21 companies · $294 in 2025
The $294 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $137 · 2020: $236 · 2021: $424 · 2022: $426 · 2023: $344 · 2024: $274 · 2025: $294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $913.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $912.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $317.22 | 2019-2025 | |
| Ardelyx, INC. | $185.48 | 2022-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $173.45 | 2019-2023 | Entyvio |
| Phathom Pharmaceuticals, INC. | $148.98 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $148.58 | 2019-2025 | Xifaxan, Plenvu |
| Merck Sharp & Dohme LLC | $139.34 | 2019-2024 | Dificid, Zinplava |
| Redhill Biopharma INC. | $121.91 | 2020-2024 | Talicia |
| Janssen Biotech, INC. | $115.51 | 2019-2025 | Tremfya, Stelara |
| Gilead Sciences, INC. | $113.73 | 2020-2023 | |
| Nestle Healthcare Nutrition INC. | $96.60 | 2020-2023 | |
| Qol Medical, LLC | $81.17 | 2023-2024 | Sucraid, Sucraid |
| Madrigal Pharmaceuticals | $78.04 | 2024-2025 | Rezdiffra, Resmetirom |
| Ironwood Pharmaceuticals, INC | $74.79 | 2019-2024 | |
| Intercept Pharmaceuticals, INC. | $69.76 | 2022-2023 | Ocaliva |
| Braintree Laboratories, INC. | $53.15 | 2021-2023 | Sutab |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $50.32 | 2022-2024 | Dupixent |
| Allergan, INC. | $48.07 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $34.96 | 2022-2024 | Rebyota |
| Pfizer INC. | $34.50 | 2019-2024 | |
| Evoke Pharma, INC. | $27.49 | 2021 | |
| Vivus LLC | $22.83 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederick Oni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.